work
sens notabl shift investor sentiment gilead
past week analyst brief san francisco recent manag
posit busi fundament reced headwind recent
reiter neutral thesi shift investor sentiment potenti
stabil busi prompt us ask work year analysi
push pull busi demonstr initi thesi
gilead supertank acceler get increment closer
yet near term posit catalyst expect next two
three month expect stock continu recent perform
set apart biopharma name cover
street manag take larg bet novel differenti scienc
translat signific benefit patient among best industri
benefit manifest larg revenu stream compani
prudent manag term margin earn leverag
hcv busi boon anvil around neck lead
superl initi bolu revenu possibl much smaller cash cow annuiti
stream eventu stabil howev busi price strategi
sulli shine air pocket patient startsbegin
competit compress sale earn margin
neutral thesi base view next month still
better chanc number come model
earn bottom sale potenti howev competit
patient dynam hcv loss exclus hiv product
could dampen bic/f/taf yescarta launch
flip side see strong bic/f/taf launch analog
genvoya could add adjust ep clinic catalyst
nash filgotinib improv visibl margin benefit
hcv minim potenti tax reform uplift could
believ increment closer becom growth stori
need high certainti forward number grow grow faster
rate expect posit yet
near term posit catalyst could drive stock perform appeal
medicin area unmet medic
need gilead portfolio product
pipelin investig drug
includ treatment hiv/aid liver
inflammatori
respiratori diseas cardiovascular
analyst certif import disclosur see disclosur appendix
initi coverag gilead perform rate
sinc launch hcv product late
share roller coaster ride
street first underappreci potenti hcv
surpris franchis declin worst-off patient
cure hcv busi trough near term one two
year resurg hiv busi growth addit kite
axi-cel nash off-set flat sales/non-gaap ep
opco model less-than-averag rel
peer-group metric believ risk/reward balanc
hcv sale trough/slow declin next one two year
hiv busi launch taf-bas regimen bic/f/taf
make solid growth busi
yescarta axi-cel launch across us eu meet
expect sale
nash franchis lead product selonsertib approv
market
cardiovascular/oth busi sale reduc
due gener competit
non-gaap oper margin declin
phase data psc tirabrutinib phase interim
data gastric cancer
selonsertib top-lin phase data nash stellar
complet list upcom mileston exhibit
hcv sale trough next one two year flat/slightli
patient diagnos treat
hiv busi outperform expect
axi-cel us/eu launch beat reduc expect provid
abl slow margin declin
hcv busi continu declin precipit rate near
hiv busi growth minim best next two five year
axi-cel us/eu launch underperform reduc expect due
car-t side-effect manufactur reimburs concern
nash franchis gain traction clinic data
mediocr best even among nash patient fibrosi
past year gild hcv franchis subject signific sale
downgrad new patient start price durat therapi market share
reimburs contract pressur
trend also led earn downgrad pressur margin
constant sale earn downgrad made gild valuat price-to-earnings basi
start look stretch
made case previous street potenti discount
sales/earn trough
current consensu suggest sale earn downgrad might still
room play
exhibit product sale histor expect
model line consensu project sale progress
consensu earn margin
expect steadi declin margin go forward potenti room downsid
kite car-t product higher cog least short run
hcv continu compress
hiv product launch lead increas sale market cost
loss exclus loe hiv product play
exhibit opco product sale margin structur histor
neutral thesi base belief might see sales/earn
trough still better probabl hcv number continu come
albeit slower rate bic/f/taf launch stellar
rapid enough make hcv loss hiv
per recent analysi us longer cheap
bloomberg compani report oppenheim co result present view indic futur perform
pose question upsid risk thesi
hiv
approv rapid launch bic/f/taf regimen clearli
import event
recent sell-sid updat san francisco earli januari laid follow
framework compel bic/f/taf launch
anticip us launch pdufa eu launch
believ approv success launch product
import competit viewpoint also gild hiv
sale margin see exhibit
almost treatment-nav switch patient enrol across four phase
factoid beli interest color channel
check end four phase studi data collect
valid analysi complet almost record time
file fda approv june prioriti review voucher
grant expedit review
believ furiou activ impli seriou focu
commit manag get potenti game-chang
therapi market
four phase studi met primari endpoint non-inferior
bic/f/taf regimen smallest integrase-contain single-t regimen
inform member media written gild
regimen non-inferior equal versu superior gsk
approv integras inhibitor laud gsk two-drug
regimen would caution rare compani one two
product sale bag like gsk beat compani like
seven nine market hiv product
amgn hematopoiesi busi epogen aranesp
neulasta biib ms busi exampl franchis
multipl product form difficult contract market barrier
overcom expect littl differ especi light
consensu sale gsk triumeq/tivicay per bloomberg
versu bic/f/taf consensu opco
genvoya gild boost integrase-contain regimen launch
late elvitegravir/cobicistat/ftc/taf one
drug launch accru sale
doubl
model bic/f/taf sale vs consensu
two three month less bic/f/taf launch
versu genvoya
frame refer bic/f/taf launch mimic
genvoya launch patient bic/f/taf came
compet regimen would benefit
adjust ep
bic/f/taf resist develop observ across studi
frame comparison resist monotherapi
dolutegravir gsk integras inhibitor alreadi report
combin treatment vast major dolutegravir treatment
resist dolutegravir rare continu
favor renal bone profil accord peopl live
hiv us year age
model hiv sale line consensu
believ better chanc gild hiv
perform beat consensu expect need
see three four quarter bic/f/taf sale uptak updat
expect
long-await hcv trough
recent commentari variou investor confer indic
variabl regard hcv busi competit almost set stabl
two viabl competitor hcvgild abba two
compani approv pan-genotyp regimen
also accord two variabl play hcv market share
new patient start compet market share new patient start
control bolu initi hcv patient work way system
bloomberg expect gild hcv franchis sale vs
model swing either direct worth adjust ep
hcv matter less still neg posit affect gild
perhap aspect stori get us excit
valuat benefit franchis assum
sale vs enough estim bloomberg
rel paltri model believ upsid
burgeon nash franchis monotherapi combin ask-
approach could multipl gain visibl
filgotinib galapagos-partn product sale model yet
phase data ra biolog inadequ respond finch studi
expect
continu increment pipelin data flow hiv look maintain
domin area current develop focu new modal like
long-act inject product molecul treatment-resist hiv
 spend around hcv close zero pan-genotyp cure rate
mid-to-high rang
import clinic catalyst year follow
earli stage phase data combin agent
possibl easl april
phase finch data filgotinib
stellar phase data studi potenti complet
recruit januari
approv pdufa februari cohort phase studi hiv phase studi approv phase studi nivolumab gastric efficaci analysi phase studi gastric endpoint phase combin studi r/r phase studi ebola survivorsnash pbc psc phase studi ahcomplet enrol stellar phase studi enrol stellar phase studi endpoint analysi phase phase studi analysi phase studi phase studi ankylos phase studi psoriat phase studi lung transplant phase studi adult upper respiratori tract analysi phase studi phase studi sjogren syndrom cutan lupu erythematosu phase later perform na
consensu adjust gross
oper margin respect term gild margin structur note
abl expect maintain close industri margin bloomberg
data margin basi see exhibit
impress hcv busi among gild profit
deceas sale peak speak manag
fiscal rectitud focu fundament even difficult time compani
note ceas activ hcv posit margin contributor
long tail hcv cure work us ex-u health
also expect yescarta launch drag margin near term
also note gild guidanc tax rate rang
earn call recent tax reform act pass us govern could
reduc rate depend gild geograph sale distribut tax
credit accrual
estim valuat uplift tax come area
median averag median averag celg adj ep growth remov due small base effect gross marginnet incom ep gilead scienc inc
product epclusa- vosevi- hcv descovy- vemlidy- bic/ftc/taf- hiv total axi-cel- selonsirtib- total total product perform na
statement million except per product royalti contract total good research sell gener non-gaap oper non-gaap oper non-gaap incom expens interest non-gaap incom incom incom tax non-gaap net net loss attribut non control net incom attribut dilut dilut share adjust comp gross oper incom tax inc
stock price compani mention report
